Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00986921 · ClinicalTrials.gov registry record · NA
Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks
A NA study of Abortion, sponsored by Boston University.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00986921 is a NA study of Abortion that has completed, run by Boston University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00986921, a NA study of Abortion, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Women who are requesting pregnancy termination at 14-16 weeks, who would normally have osmotic dilator insertion the day before their procedure, would be asked if they wanted to participate. Participants would be randomized to two groups: first, dilator insertion as usual, or second, mifepristone taken the day before the procedure.
Conditions Studied
Interventions
- DRUG mifepristone 200 mg
- DEVICE osmotic dilator insertion
Study Locations (1)
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00986921
The ClinicalTrials.gov registry entry for NCT00986921 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Abortion appearing as the primary indexed condition, and to 2 interventions - of which mifepristone 200 mg is the first listed.
NCT00986921 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00986921 about?
NCT00986921 is a clinical study titled "Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks". Women who are requesting pregnancy termination at 14-16 weeks, who would normally have osmotic dilator insertion the day before their procedure, would be asked if they wanted to participate. Participants would be randomized to two groups: first, dilator insertion as usual, or second, mifepristone ta...
What is the current status of trial NCT00986921?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2009-10. Estimated completion is 2011-03.
What conditions does trial NCT00986921 study?
This clinical trial studies the following conditions: Abortion.
What interventions are being tested in trial NCT00986921?
The interventions under investigation include: mifepristone 200 mg (DRUG), osmotic dilator insertion (DEVICE).
Who is sponsoring clinical trial NCT00986921?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00986921 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Abortion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.